Investigators

Summary

Dr. Glorioso has spent his career studying the molecular biology and immunology of HSV and the last 20 years developing HSV gene vectors for local and systemic therapies. He is a world-wide leader in this field and has the expertise to develop the technology related to the treatment of diseases of the peripheral and central nervous system. His interest in peripheral nerve disease has included nerve degeneration due to diabetes and cancer drug therapies that have led to treatments of animal models. Studies to understand the pathophysiology of chronic pain and the identification of gene therapy interventions that create effective pain therapies have been long standing interests and he was among the first to develop HSV vectors to treat pain. This research has culminated in clinical trials for treatment of cancer-related and arthritis pain. Dr. Glorioso has also focused his attention on neurodegenerative diseases that include SCA1 deficiency Alzheimer’s and Huntington's disease and the development of oncolytic vectors to treat brain tumors. Part of this research extends his application of HSV vectors for systemic delivery for treatment of metastatic cancer and muscular dystrophy. He has also recently developed HSV vectors for the creation and neuronal differentiation of human iPS cells derived from fetal brain and human dermal fibroblasts. His vector technology has been licensed to numerous biotech companies in which Dr. Glorioso serves as founder and/or consultant.